查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601096

多癌篩檢市場：按產品類型、測試類型、技術、癌症類型、最終用戶 - 2025-2030 年全球預測

Multicancer Screening Market by Product (AI and Machine Learning-Based Platforms, Blood-Based Tests, Breath Analysis Tests), Test Type (In-vitro diagnostics, Laboratory Developed Tests), Technology, Cancer Type, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年多篩檢市場價值為14億美元，預計2024年將達到15.3億美元，複合年成長率為9.90%，預計到2030年將達到27.2億美元。

多癌篩檢代表了早期癌症檢測的革命性轉變，旨在在症狀出現之前透過一次測試識別多種癌症類型。由於癌症發病率和死亡率不斷上升，這種方法變得越來越必要，這凸顯出早期檢測對於提高存活率至關重要。多種癌症篩檢預計將主要應用於臨床環境和常規健康檢查，以促進早期發現高風險族群，例如有癌症家族病史或遺傳傾向的人。最終用途範圍主要包括醫院、診斷實驗室和癌症研究中心。推動市場成長的是基因組學和生物資訊學的技術進步，這些技術進步使得癌症生物標記的檢測更加準確和全面。人工智慧在資料分析中的整合也有助於擴展多種癌症篩檢能力。此外，公眾意識的提高和個人化醫療的採用正在創造潛在的機會。然而，高成本、監管障礙以及測試敏感性和特異性問題等挑戰可能會阻礙市場成長。有關遺傳資訊的倫理考量和資料隱私問題變得更加複雜。為了克服這些限制，需要進行研究，重點是透過技術創新降低成本並提高檢測精度。新型生物標記的整合以及使用人工智慧進行高級風險評估可以極大地推動創新。研究更好的資料管理工具和安全平台來處理敏感的遺傳資訊也至關重要。透過與專門從事人工智慧和巨量資料分析的高科技公司合作，還有機會改善檢測演算法並改善患者治療結果。總體而言，只要克服這些挑戰並最佳化最尖端科技的應用以滿足不斷變化的醫療保健需求，多癌症篩檢市場有望顯著成長。

主要市場統計
基準年[2023] 14億美元
預測年份 [2024] 15.3億美元
預測年份 [2030] 27.2億美元
複合年成長率（%） 9.90%

市場動態：揭示快速發展的多種癌症篩檢市場的關鍵市場洞察

供需的動態交互作用正在改變多種篩檢市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 癌症盛行率增加和老化速度加快
    • 多項政府措施促進醫療機構中的多種癌症篩檢
  • 市場限制因素
    • 與多種篩檢相關的耗時程序和高成本
  • 市場機會
    • 液態切片的潛在利用和多癌症檢測 (MCD) 研究中心的增加
    • 活性化癌症診斷和治療方法開發的研究開發活動
  • 市場挑戰
    • 安全性和有效性資料不足，對測試性能變化的擔憂

波特五力：駕馭多種癌症篩檢市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解多種篩檢市場的外部影響

外部宏觀環境因素在塑造多癌症篩檢市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解多癌症篩檢市場的競爭狀況

對多種篩檢市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣多癌症篩檢市場供應商的績效評估

FPNV定位矩陣是評估多癌症篩檢市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：全面分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症發生率增加和人口老化
      • 政府努力促進醫療機構中的多種癌症篩檢
    • 抑制因素
      • 多種癌症篩檢過程耗時且高成本
    • 機會
      • 液態生物檢體的潛在用途和多種癌症檢測 (MCD) 研究中心的興起
      • 增加癌症診斷治療程序的研發活動
    • 任務
      • 對安全性和有效性資料不足以及測試性能變化的擔憂
  • 市場區隔分析
    • 產品：透過人工智慧驅動的篩檢和診斷技術的突破性創新改善早期癌症檢測
    • 測試類型：體外診斷和實驗室開發的測試是早期癌症檢測和改善患者預後的首選。
    • 技術：PCR 因其早期檢測效率和準確性而受到青睞
    • 癌症類型：透過多學科篩檢的進步關注創新和可及性
    • 最終用戶：協調創新和護理，解決學術、診斷和醫療保健領域的多個癌症篩檢優先事項
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章多種癌症篩檢市場：依產品

  • 基於人工智慧和機器學習的平台
  • 驗血
  • 呼氣分析測試
  • 糞便檢查
  • 基因組/測試組
  • 影像檢查
    • 電腦斷層掃描
    • 磁振造影
    • 正子斷層掃描
  • 唾液和口腔拭子測試
  • 組織檢查
  • 尿液檢查

第7章按測試類型分類的多種癌症篩檢市場

  • 體外診斷
  • 實驗室開發測試

第8章多種癌症篩檢市場：依技術分類

  • 螢光原位雜合技術
  • 免疫組織化學
  • 次世代定序
  • 聚合酵素鏈鎖反應

第9章按癌症類型分類的多種癌症篩檢市場

  • 大腦/神經系統
  • 乳房/婦科
  • 內分泌
  • 胃腸道
  • 泌尿生殖系統
  • 造血系統惡性
  • 肺
  • 肉瘤
  • 皮膚

第 10 章 多種癌症篩檢市場：依最終用戶分類

  • 學術/研究機構
  • 診斷和臨床實驗室
  • 醫院

第11章美洲多種癌症篩檢市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區多種癌症篩檢市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲多癌症篩檢市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 策略性資金籌措將加速 Freenome 早期癌症檢測技術的進步
    • PanGIA Biotech 利用液態生物檢體平台改進致癌性疾病的檢測
    • Exact Sciences Corp. 的遺傳性癌症篩檢測試「Riskguard」簡介
    • SeekIn Inc. 和 Oncolnv 策略聯盟加強全球癌症檢測工作
    • AnchorDx 和 DiaCarta 之間的合作將徹底改變全球癌症檢測
    • 燃石生物科技的 OverC 多槍檢測血液檢測獲得全球認可
    • Elypta 獲得 ISO 13485:2016 認證，推動基於 GAGome 的多種癌症檢測
    • Freenome 的策略性收購透過 Oncimmune Ltd 的先進診斷技術增強了癌症檢測能力
    • Lucens 透過創新的 MCED 血液檢測改善癌症檢測：在美國的策略公告

公司名單

  • ANPAC Bio-Medical Science Co., Ltd.
  • Burning Rock Biotech Limited
  • Caris Life Sciences
  • Coyne Medical Ltd.
  • Delfi Diagnostics, Inc.
  • Elypta AB
  • EpiCypher, Inc.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Foundation Medicine, Inc.
  • Freenome Holdings, Inc.
  • Fulgent Genetics, Inc.
  • Gene Solutions
  • Grail, LLC by Illumina, Inc.
  • Guangzhou AnchorDx Medical Co., Ltd.
  • Guardant Health, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Lucence Health Inc.
  • Micronoma, Inc.
  • MiRXES Pte Ltd.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Naveris, Inc.
  • NeoGenomics Laboratories
  • OneTest
  • Siemens Healthineers AG
  • StageZero Life Sciences. Ltd.
Product Code: MRR-5C6F41F5AFE7

The Multicancer Screening Market was valued at USD 1.40 billion in 2023, expected to reach USD 1.53 billion in 2024, and is projected to grow at a CAGR of 9.90%, to USD 2.72 billion by 2030.

Multicancer screening represents an innovative shift in early cancer detection, aiming to identify multiple cancer types through a single test before symptoms appear. This approach has become increasingly necessary due to rising cancer incidence and mortality rates, underscoring the critical need for early detection to improve survival rates. Multicancer screening is projected to be applied primarily in clinical settings and routine health check-ups, enhancing early detection among high-risk populations, such as those with a family history of cancer or existing genetic predispositions. The end-use scope primarily includes hospitals, diagnostic laboratories, and cancer research centers. Market growth is fueled by technological advancements in genomics and bioinformatics, allowing for more accurate and comprehensive detection of cancer biomarkers. The integration of AI in data analysis also contributes to the expansion of multicancer screening capabilities. Additionally, increasing public awareness and the adoption of personalized medicine are generating potential opportunities. However, challenges such as high costs, regulatory hurdles, and issues related to the sensitivity and specificity of tests can impede market growth. Ethical considerations and data privacy concerns regarding genetic information further add complexity. To overcome these limitations, research should focus on reducing costs through technological innovation and enhancing test accuracy. The integration of novel biomarkers and leveraging AI for advanced risk assessment could significantly propel innovation. Researching better data management tools and secure platforms for handling sensitive genetic information is also vital. Opportunities lie in partnerships with tech firms specializing in AI and big data analytics to refine detection algorithms and improve patient outcomes. Overall, the multicancer screening market is poised for substantial growth, contingent upon overcoming these challenges and optimizing the application of cutting-edge technologies to meet evolving healthcare demands.

KEY MARKET STATISTICS
Base Year [2023] USD 1.40 billion
Estimated Year [2024] USD 1.53 billion
Forecast Year [2030] USD 2.72 billion
CAGR (%) 9.90%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Multicancer Screening Market

The Multicancer Screening Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cancer disease and rising aging population
    • Several government initiatives promoting multicancer screening in healthcare facilities
  • Market Restraints
    • Time-consuming procedures coupled with high cost associated with multicancer screening
  • Market Opportunities
    • Potential utilization of liquid biopsy and rising multicancer detection (MCD) research centers
    • Rising R&D activities for the development of cancer diagnostics treatment procedures
  • Market Challenges
    • Concerns associated with adequate safety and efficacy data and variability in test performance

Porter's Five Forces: A Strategic Tool for Navigating the Multicancer Screening Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Multicancer Screening Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Multicancer Screening Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Multicancer Screening Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Multicancer Screening Market

A detailed market share analysis in the Multicancer Screening Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Multicancer Screening Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Multicancer Screening Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Multicancer Screening Market, highlighting leading vendors and their innovative profiles. These include ANPAC Bio-Medical Science Co., Ltd., Burning Rock Biotech Limited, Caris Life Sciences, Coyne Medical Ltd., Delfi Diagnostics, Inc., Elypta AB, EpiCypher, Inc., Epigenomics AG, Exact Sciences Corporation, Foundation Medicine, Inc., Freenome Holdings, Inc., Fulgent Genetics, Inc., Gene Solutions, Grail, LLC by Illumina, Inc., Guangzhou AnchorDx Medical Co., Ltd., Guardant Health, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Lucence Health Inc., Micronoma, Inc., MiRXES Pte Ltd., Myriad Genetics, Inc., Natera, Inc., Naveris, Inc., NeoGenomics Laboratories, OneTest, Siemens Healthineers AG, and StageZero Life Sciences. Ltd..

Market Segmentation & Coverage

This research report categorizes the Multicancer Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across AI and Machine Learning-Based Platforms, Blood-Based Tests, Breath Analysis Tests, Fecal Tests, Gene Panels/Test Panels, Imaging Tests, Saliva & Buccal Swab Test, Tissue Test, and Urine-Based Tests. The Imaging Tests is further studied across Computed Tomography, Magnetic Resonance Imaging, and Positron Emission Tomography.
  • Based on Test Type, market is studied across In-vitro diagnostics and Laboratory Developed Tests.
  • Based on Technology, market is studied across Fluorescence In-Situ Hybridization, Immunohistochemistry, Next-Generation Sequencing, and Polymerase Chain Reaction.
  • Based on Cancer Type, market is studied across Brain/Nervous System, Breast & Gynecologic, Endocrine, Gastrointestinal, Genitourinary, Hematological Malignancies, Lung, Sarcoma, and Skin.
  • Based on End User, market is studied across Academic & Research Institutions, Diagnostic & Clinical Laboratories, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer disease and rising aging population
      • 5.1.1.2. Several government initiatives promoting multicancer screening in healthcare facilities
    • 5.1.2. Restraints
      • 5.1.2.1. Time-consuming procedures coupled with high cost associated with multicancer screening
    • 5.1.3. Opportunities
      • 5.1.3.1. Potential utilization of liquid biopsy and rising multicancer detection (MCD) research centers
      • 5.1.3.2. Rising R&D activities for the development of cancer diagnostics treatment procedures
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with adequate safety and efficacy data and variability in test performance
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Improvement in early cancer detection through revolutionary innovations in ai-enhanced screening and diagnostic technologies
    • 5.2.2. Test Type: In-vitro diagnostics and laboratorydeveloped tests are preferred for early cancer detection and improve patient outcomes
    • 5.2.3. Technology: Significant preference toward PCR for its efficiency in early detection and accuracy
    • 5.2.4. Cancer Type: Emphasizing innovation and accessibility through advancement in the multispeciality screening
    • 5.2.5. End-User: Harmonizing innovation and care to navigate multi cancer screening priorities across academic, diagnostic, and healthcare sectors
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Multicancer Screening Market, by Product

  • 6.1. Introduction
  • 6.2. AI and Machine Learning-Based Platforms
  • 6.3. Blood-Based Tests
  • 6.4. Breath Analysis Tests
  • 6.5. Fecal Tests
  • 6.6. Gene Panels/Test Panels
  • 6.7. Imaging Tests
    • 6.7.1. Computed Tomography
    • 6.7.2. Magnetic Resonance Imaging
    • 6.7.3. Positron Emission Tomography
  • 6.8. Saliva & Buccal Swab Test
  • 6.9. Tissue Test
  • 6.10. Urine-Based Tests

7. Multicancer Screening Market, by Test Type

  • 7.1. Introduction
  • 7.2. In-vitro diagnostics
  • 7.3. Laboratory Developed Tests

8. Multicancer Screening Market, by Technology

  • 8.1. Introduction
  • 8.2. Fluorescence In-Situ Hybridization
  • 8.3. Immunohistochemistry
  • 8.4. Next-Generation Sequencing
  • 8.5. Polymerase Chain Reaction

9. Multicancer Screening Market, by Cancer Type

  • 9.1. Introduction
  • 9.2. Brain/Nervous System
  • 9.3. Breast & Gynecologic
  • 9.4. Endocrine
  • 9.5. Gastrointestinal
  • 9.6. Genitourinary
  • 9.7. Hematological Malignancies
  • 9.8. Lung
  • 9.9. Sarcoma
  • 9.10. Skin

10. Multicancer Screening Market, by End User

  • 10.1. Introduction
  • 10.2. Academic & Research Institutions
  • 10.3. Diagnostic & Clinical Laboratories
  • 10.4. Hospitals

11. Americas Multicancer Screening Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Multicancer Screening Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Multicancer Screening Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Strategic Funding Fuels Freenome's Advancement in Early Cancer Detection Technology
    • 14.3.2. PanGIA Biotech Advances Multi-Cancer Detection with Liquid Biopsy Platform
    • 14.3.3. Introduction of Riskguard, A Hereditary Cancer Screening Test by Exact Sciences Corp
    • 14.3.4. Strategic Partnership Between SeekIn Inc. and Oncolnv to Enhance Global Cancer Detection Efforts
    • 14.3.5. Collaboration Between AnchorDx and DiaCarta to Revolutionize Global Cancer Screening
    • 14.3.6. Burning Rock Biotech Achieves Global Recognition with OverC Multi-Cancer Detection Blood Test
    • 14.3.7. Elypta Attains ISO 13485:2016 Certification, Advancing GAGome-Based Multicancer Detection
    • 14.3.8. Strategic Acquisition by Freenome Amplifies Cancer Screening Capabilities through Oncimmune Ltd's Advanced Diagnostics
    • 14.3.9. Lucence Advances Cancer Detection with Innovative MCED Blood Test: A Strategic Unveiling in the U.S.

Companies Mentioned

  • 1. ANPAC Bio-Medical Science Co., Ltd.
  • 2. Burning Rock Biotech Limited
  • 3. Caris Life Sciences
  • 4. Coyne Medical Ltd.
  • 5. Delfi Diagnostics, Inc.
  • 6. Elypta AB
  • 7. EpiCypher, Inc.
  • 8. Epigenomics AG
  • 9. Exact Sciences Corporation
  • 10. Foundation Medicine, Inc.
  • 11. Freenome Holdings, Inc.
  • 12. Fulgent Genetics, Inc.
  • 13. Gene Solutions
  • 14. Grail, LLC by Illumina, Inc.
  • 15. Guangzhou AnchorDx Medical Co., Ltd.
  • 16. Guardant Health, Inc.
  • 17. Invitae Corporation
  • 18. Laboratory Corporation of America Holdings
  • 19. Lucence Health Inc.
  • 20. Micronoma, Inc.
  • 21. MiRXES Pte Ltd.
  • 22. Myriad Genetics, Inc.
  • 23. Natera, Inc.
  • 24. Naveris, Inc.
  • 25. NeoGenomics Laboratories
  • 26. OneTest
  • 27. Siemens Healthineers AG
  • 28. StageZero Life Sciences. Ltd.

LIST OF FIGURES

  • FIGURE 1. MULTICANCER SCREENING MARKET RESEARCH PROCESS
  • FIGURE 2. MULTICANCER SCREENING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD THOUSAND)
  • FIGURE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 6. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 16. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 18. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 20. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 24. MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MULTICANCER SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD THOUSAND)
  • TABLE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 6. MULTICANCER SCREENING MARKET DYNAMICS
  • TABLE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AI AND MACHINE LEARNING-BASED PLATFORMS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BLOOD-BASED TESTS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREATH ANALYSIS TESTS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY FECAL TESTS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANELS/TEST PANELS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 16. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 17. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 18. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SALIVA & BUCCAL SWAB TEST, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 19. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TISSUE TEST, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 20. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY URINE-BASED TESTS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 21. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 22. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IN-VITRO DIAGNOSTICS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 23. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TESTS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 24. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 25. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY FLUORESCENCE IN-SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 26. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 27. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 28. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 29. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 30. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BRAIN/NERVOUS SYSTEM, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 31. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST & GYNECOLOGIC, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 32. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY ENDOCRINE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 33. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 34. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENITOURINARY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 35. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 36. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 37. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SARCOMA, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 38. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SKIN, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 39. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 40. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 41. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC & CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 42. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 43. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 44. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 45. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 46. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 47. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 48. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 49. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 50. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 51. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 52. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 53. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 54. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 55. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 56. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 57. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 58. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 59. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 60. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 61. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 62. CANADA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 63. CANADA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 64. CANADA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 65. CANADA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 66. CANADA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 67. CANADA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 68. MEXICO MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 69. MEXICO MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 70. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 71. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 72. MEXICO MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 73. MEXICO MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 74. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 75. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 76. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 77. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 78. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 79. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 80. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2018-2030 (USD THOUSAND)
  • TABLE 81. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 82. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 83. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 84. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 85. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 86. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 87. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 88. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 89. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 90. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 91. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 92. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 93. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 94. CHINA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 95. CHINA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 96. CHINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 97. CHINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 98. CHINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 99. CHINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 100. INDIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 101. INDIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 102. INDIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 103. INDIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 104. INDIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 105. INDIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 106. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 107. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 108. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 109. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 110. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 111. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 112. JAPAN MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 113. JAPAN MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 114. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 115. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 116. JAPAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 117. JAPAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 118. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 119. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 120. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 121. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 122. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 123. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 124. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 125. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 126. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 127. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 128. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 129. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 130. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 131. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 132. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 133. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 134. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 135. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 136. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 137. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 138. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 139. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 140. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 141. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 142. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 143. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 144. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 145. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 146. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 147. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 148. THAILAND MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 149. THAILAND MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 150. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 151. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 152. THAILAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 153. THAILAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 154. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 155. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 156. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 157. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 158. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 159. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 167. DENMARK MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 168. DENMARK MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 169. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 170. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 171. DENMARK MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 172. DENMARK MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 173. EGYPT MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 174. EGYPT MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 175. EGYPT MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 176. EGYPT MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 177. EGYPT MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 178. EGYPT MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 179. FINLAND MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 180. FINLAND MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 181. FINLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 182. FINLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 183. FINLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 184. FINLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 185. FRANCE MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 186. FRANCE MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 187. FRANCE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 188. FRANCE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 189. FRANCE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 190. FRANCE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 191. GERMANY MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 192. GERMANY MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 193. GERMANY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 194. GERMANY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 195. GERMANY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 196. GERMANY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 197. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 198. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 199. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 200. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 201. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 202. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 203. ITALY MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 204. ITALY MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 205. ITALY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 206. ITALY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 207. ITALY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 208. ITALY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 209. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 210. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 211. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 212. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 213. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 214. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 215. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 216. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 217. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 218. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 219. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 220. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 221. NORWAY MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 222. NORWAY MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 223. NORWAY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 224. NORWAY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 225. NORWAY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 226. NORWAY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 227. POLAND MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 228. POLAND MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 229. POLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 230. POLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 231. POLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 232. POLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 233. QATAR MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 234. QATAR MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 235. QATAR MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 236. QATAR MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 237. QATAR MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 238. QATAR MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 239. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 240. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 241. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 242. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 243. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 244. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 245. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 246. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 247. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 248. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 249. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 250. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 251. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 252. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 253. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 254. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 255. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 256. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 257. SPAIN MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 258. SPAIN MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 259. SPAIN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 260. SPAIN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 261. SPAIN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 262. SPAIN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 263. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 264. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 265. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 266. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 267. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 268. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 269. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 270. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 271. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 272. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 273. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 274. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 275. TURKEY MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 276. TURKEY MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 277. TURKEY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 278. TURKEY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 279. TURKEY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 280. TURKEY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 281. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 282. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 283. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 284. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 285. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 286. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 287. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
  • TABLE 288. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
  • TABLE 289. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 290. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 291. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 292. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 293. MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 294. MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2023